ASLN Aslan Pharmaceuticals Ltd ADR

USD 0.68 -0.06 -7.482993
Icon

Aslan Pharmaceuticals Ltd ADR Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.68

-0.06 (-7.48)%

USD 0.01B

0.10M

USD 15.67(+2,203.92%)

N/A

Icon

ASLN

Aslan Pharmaceuticals Ltd ADR (USD)
COMMON STOCK | NSD
USD 0.68
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.01B

N/A

USD 0.68

Aslan Pharmaceuticals Ltd ADR Stock Forecast

Show ratings and price targets of :
USD 15.67
(+2,203.92%)

Based on the Aslan Pharmaceuticals Ltd ADR stock forecast from 2 analysts, the average analyst target price for Aslan Pharmaceuticals Ltd ADR is USD 15.67 over the next 12 months. Aslan Pharmaceuticals Ltd ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aslan Pharmaceuticals Ltd ADR is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Aslan Pharmaceuticals Ltd ADR’s stock price was USD 0.68. Aslan Pharmaceuticals Ltd ADR’s stock price has changed by -29.43% over the past week, -36.15% over the past month and -75.27% over the last year.

No recent analyst target price found for Aslan Pharmaceuticals Ltd ADR
No recent average analyst rating found for Aslan Pharmaceuticals Ltd ADR

Company Overview Aslan Pharmaceuticals Ltd ADR

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1...Read More

https://aslanpharma.com

83 Clemenceau Avenue, Singapore, Singapore, 239920

34

December

USD

USA

Adjusted Closing Price for Aslan Pharmaceuticals Ltd ADR (ASLN)

Loading...

Unadjusted Closing Price for Aslan Pharmaceuticals Ltd ADR (ASLN)

Loading...

Share Trading Volume for Aslan Pharmaceuticals Ltd ADR Shares

Loading...

Compare Performance of Aslan Pharmaceuticals Ltd ADR Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ASLN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Aslan Pharmaceuticals Ltd ADR (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -3.15 (-0.90%) USD91.42B 26.68 16.84

ETFs Containing ASLN

Symbol Name ASLN's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Aslan Pharmaceuticals Ltd ADR (ASLN) Stock

Based on ratings from 2 analysts Aslan Pharmaceuticals Ltd ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.

Unfortunately we do not have enough data on ASLN's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for ASLN is USD 15.67 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 15.

ASLN stock's Price/Earning ratio is 0.10. Our analysis grades ASLN stock's Price / Earning ratio at B. This means that ASLN stock's Price/Earning ratio is above 14% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ASLN may be undervalued for its sector.

The last closing price of ASLN's stock was USD 0.68.

The most recent market capitalization for ASLN is USD 0.01B.

Based on targets from 2 analysts, the average taret price for ASLN is projected at USD 15.67 over the next 12 months. This means that ASLN's stock price may go up by +2,203.92% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...